BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/27/2021 9:41:33 AM | Browse: 540 | Download: 1187
 |
Received |
|
2021-01-20 10:02 |
|
Peer-Review Started |
|
2021-01-20 10:04 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-02-09 19:27 |
|
Revised |
|
2021-02-23 11:41 |
|
Second Decision |
|
2021-04-08 07:41 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-04-13 14:35 |
|
Articles in Press |
|
2021-04-13 14:35 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-05-06 22:28 |
|
Typeset the Manuscript |
|
2021-05-19 00:14 |
|
Publish the Manuscript Online |
|
2021-05-27 09:41 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Review |
| Article Title |
Towards a new era of hepatitis B virus therapeutics: The pursuit of functional cure
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Efthymios P Tsounis, Evanthia Tourkochristou, Athanasia Mouzaki and Christos Triantos |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Christos Triantos, FAASLD, MD, PhD, Assistant Professor, Division of Gastroenterology, Department of Internal Medicine, Medical School, University of Patras, D. Stamatopoulou 4, Rio, Patras 26504, Greece. chtriantos@hotmail.com |
| Key Words |
Chronic hepatitis B; Functional cure; Direct-acting antivirals; Gene silencing; Immunotherapy; Therapeutic vaccination |
| Core Tip |
Despite preventive vaccination and effective anti-viral drugs, approximately 300 million people worldwide are at risk of liver-related morbidity and mortality from hepatitis B virus (HBV) infection. In the search for more effective strategies, research has focused on two broad categories of therapeutic interventions. First, direct-acting antivirals that interrupt various stages of the HBV life cycle are yielding promising results in clinical trials and suppress HBV antigen load. Second, the need to address depleted immune responses and revive the tolerogenic liver microenvironment has brought immunotherapies to the forefront. It is likely that HBV elimination will occur through an upcoming treatment that combines agents from both classes. |
| Publish Date |
2021-05-27 09:41 |
| Citation |
Tsounis EP, Tourkochristou E, Mouzaki A, Triantos C. Towards a new era of hepatitis B virus therapeutics: the pursuit of functional cure. World J Gastroenterol 2021; 27(21): 2727-2757 |
| URL |
https://www.wjgnet.com/1007-9327/full/v27/i21/2727.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v27.i21.2727 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
